This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Tuesday's Winners & Losers: Garmin

Shares of navigation devices maker Garmin (GRMN) fell after a rival warned of lower first-quarter revenues.

Shares of Garmin were down $4.23, or 8%, to $48.47 after its competitor TomTom said first-quarter revenue would be lower than its earlier forecast following price cuts leading up to the introduction of new models, as well as the reduction of inventory by retailers in Europe.

Meanwhile, Repligen (RGEN) said Tuesday that it settled its patent infringement suit -- dating back to January 2006 -- with Bristol-Myers Squibb (BMY) regarding rheumatoid arthritis treatment Orencia.

The news gave Repligen's shares a 79-cent, or 14%, bump to $6.23.

Shares of weight management and fitness program provider NutriSystem (NTRI) jumped 24.4% to $18.59. The Horsham, Pa.-based company announced that president and COO Joseph Redling will replace CEO Michael Hagan effective May 1. Hagan will continue to serve as nonexecutive chairman. NutriSystem also forecast first-quarter revenue of about $216 million, ahead of the Thomson Financial consensus estimate of $203.5 million. Boenning & Scattergood upgraded the stock to market perform from market underperform.

Metro PCS (PCS) added $1.11, or 5.9%, to $20.00 after the company said it added approximately 960,000 gross new subscribers, representing a 15% increase over the first quarter of 2007. The stock was also upgraded to outperform from market perform by an analyst at Wachovia.

And elsewhere, Antigenics (AGEN) rose 56 cents, or 22.7% to $3.03, after it said Tuesday that its Oncophage, a treatment for kidney cancer patients, won its first approval in Russia in patients with intermediate risk of cancer relapse. The company said it will launch in Russia in the second half of 2008 and will seek conditional approval in Europe later this year.

Oncophage is derived from each individual's tumor, and contains what the company calls the "antigenic fingerprint" of the patient's particular cancer. Thus, it's designed to reprogram the body's immune system to target only cancer cells bearing this fingerprint, according to the company.

On the losing side, Agria (GRO), a Beijing seller of upstream agricultural products for China, announced this morning that business was not disrupted by the resignation of COO Zhixin (Frank) Xue. The resignation was announced yesterday after the close. Shareholders remained skeptical, selling the company down 39.9% to $5.29.

This article was written by a staff member of

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs